{"name":"Orfagen","slug":"orfagen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"V0034 CR","genericName":"V0034 CR","slug":"v0034-cr","indication":"unknown","status":"phase_3"},{"name":"V0034CR01B vehicle","genericName":"V0034CR01B vehicle","slug":"v0034cr01b-vehicle","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"V0034 CR","genericName":"V0034 CR","slug":"v0034-cr","phase":"phase_3","mechanism":"V0034 CR is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"V0034CR01B vehicle","genericName":"V0034CR01B vehicle","slug":"v0034cr01b-vehicle","phase":"phase_3","mechanism":"Orfagen's V0034CR01B vehicle is a drug that serves as a delivery mechanism for other pharmaceuticals.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}